Long-term outcome of patients with peripheral t-cell lymphoma treated with first-line intensive chemotherapy followed by autologous stem cell transplantation

Biomedical Papers

Volumn 155, Issue 1, 2011, Pages 63-70

  Prochazka, Vit ^a   Faber, Edgar ^a   Raida, Ludek ^a   Papajik, Tomas ^a   Vondrakova, Jana ^a   Rusinakova, Zuzana ^a   Kucerova, Ladislava ^b   Myslivecek, Miroslav ^a   Indrak, Karel ^a  

^a UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^b PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Autologous transplantation; High dose chemotherapy; Peripheral T cell lymphoma; Positron emission tomography (PET)

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALE; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PERIPHERAL T CELL LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; REMISSION; SCINTISCANNING; SURVIVAL RATE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; REMISSION INDUCTION; SURVIVAL RATE;

EID: 79954496518     PISSN: 12138118     EISSN: 12138118     Source Type: Journal    
DOI: 10.5507/bp.2011.009     Document Type: Article

References (42)

1. Rüdiger T, Weisenburger DD, Anderson JR, Armitage JO, Diebold J, MacLennan KA, Nathwani BN, Ullrich F, Müller-Hermelink HK. Peripheral T-cell lymphoma (excluding anaplastic largecell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 2002;13:140-149.
2. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD and Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006;107(1):265-276.
3. Trněný M, Vášová I, Pytlík R, Belada D, Jankovská M, Kubáčková K, Šálková J, Kolešková E, Hofmanová Z. Hrabětová ŠKajaba V, Sýkorová A, Pirnos J, Přibylová, Švecová J, Čiberová J, Bolomská I, Skácelíková E, Brejcha M, Adamová D, Fraňková H, Barsová L, Benešová K, Šenigl V, Campr V, Boudová L, Stříteský J, Petrová M, Krejčová H, Procházka B, Klener P. The Non-Hodgkin's lymphoma subtypes distribution and survival in Czech Republic. Klinická onkologie 2007;20:341-348.
4. Banks PM, Warnke RA. Mature T-cell and NK-cell neoplasms. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds): World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Hematopoetic and Lymphoid Tissues. Lyon, France: IARC Press, 2001. p.189-230.
5. Ballester B, Ramuz O, Gisselbrecht C, Doucet G, Loï L, Loriod B, Bertucci F, Bouabdallah R, Devilard E, Carbuccia N, Mozziconacci MJ, Birnbaum D, Brousset P, Berger F, Salles G, Briére J, Houlgatte R, Gaulard P, Xerri L. Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas. Oncogene 2006;25(10):1560-70.
6. Geissinger E, Bonzheim I, Krenács L, Roth S, Reimer P, Wilhelm M, Müller-Hermelink HK, Rüdiger T. Nodal peripheral T-cell lymphomas correspond to distinct mature T-cell populations. J Pathol 2006;210:172-180.
7. Savage KJ. Aggressive Peripheral T-Cell Lymphomas (Specified and Unspecified Types). In: American Society of Hematology Educational Book, USA: American Society of Hematology, 2005. p 267-277
8. Coiffier B, Brousse N, Peuchmaur M, Berger F, Gisselbrecht C, Bryon PA, Diebold J. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with LNH84 regimen. J Clin Oncol 1990;9:45-50.
9. Gisselbrecht C, Gaulard P, Lepage E, Coiffier B, Brière J, Haioun C, Cazals-Hatem D, Bosly A, Xerri L, Tilly H, Berger F, Bouhabdallah R, Diebold J. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Blood 1998;92:76- 82.
10. Haioun C, Lepage E, Gisselbrecht C, Bastion Y, Coiffier B, Brice P, Bosly A, Dupriez B, Nouvel C, Tilly H, Lederlin P, Biron P, Brière J, Gaulard P, Reyes F. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude del Lymphomes de l'Adulte. J Clin Oncol 1997;15:1131-1137.
11. Rodríguez J, Caballero MD, Gutiérrez A, Marín J, Lahuerta JJ, Sureda A, Carreras E, León A, Arranz R, Fernández de Sevilla A, Zuazu J, García-Laraña J, Rifon J, Varela R, Gandarillas M, SanMiguel J, Conde E. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GELTAMO experience. Ann Oncol 2003;14:1768-1775.
12. Corradini P, Tarella C, Zallio F, Dodero A, Zanni M, Valagussa P, Gianni AM, Rambaldi A, Barbui T, Cortelazzo S. Long-term follow-up of patients with peripheral T-cell lymphomas treated upfront with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 2006;20:1533-8.
13. Reimer P. Autologous Stem Cell Transplantation as First-Line Therapy in Peripheral T-Cell Lymphomas. European Journal of Clinical & Medical Oncology 2010;2:117-124.
14. Prochazka V, Trneny M, Pytlik R, Vasova I, Kral Z, Belada D, Kozak T, Kubackova K, Siffnerova H, Matuska M, Lysy M, Bolomska I, Petrakova K, Otavova B, Pribylova J, Svecova J, Papajik T, Hamouzova M, Petrova M, Zaplet-aletal/et-alova J, Langova K. Peripheral T-cell lymphoma, unspecified--the analysis of the data from the Czech Lymphoma Study Group (CLSG) registry. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2007;151(1):103-7.
15. D'Amore F, Relander T, Lauritzen GF, Jantunen E, Hagberg H Anderson H, Cavallin-Stahl E, Holte H, Osterborg A, Merup M, Brown P, Kuittinen O, Erlanson M, Telhaug R, Gadeberg O, Sundstrom C, Delabie J, Ralfkiaer E, Vornanen M, Jensen CB. Dose-dense induction followed by autologous stem cell transplant (ASCT) leads to sustained remissions in a large fraction of patients with previously untreated peripheral T-cell lymphomas (PTCLS) - overall and subtype-specific results of phase II study from the Nordic lymphoma study group. Heamatologica 2009;94(s2):437
16. Shipp MA. Prognostic factors in aggressive non-Hodgkin's lymphoma: who has high-risk disease? Blood 1994;83(5):1165-73.
17. Sonnen R, Schmidt WP, Müller-Hermelink HK, Schmitz N. The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas. Br J Haematol 2005;129:366-372.
18. Gallamini A,Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, Morabito F, Martelli M, Brusamolino E, Iannitto E, Zaja F, Cortelazzo S, Rigacci L, Devizzi L, Todeschini G, Santini G, Brugiatelli M, Federico M, Intergruppo Italiano Linfomi. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric study. Blood 2004;103:2474-2479.
19. Rodríguez J, Conde E, Gutiérrez A, Lahuerta JJ, Arranz R, Sureda A, Zuazu J, Fernández de Sevilla A, Bendandi M, Solano C, León A, Varela MR, Caballero MD, Grupo Español de Linfomas/ Trasplante Autólogo de Médula Osea, Spanish Lymphoma/ Autologous Bone Marrow Transplant Study Group. The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/ refractory peripheral T-cell lymphoma. Haematologica 2007;92:1067-74.
20. Rodríguez J, Conde E, Gutiérrez A, Arranz R, León A, Marín J, Bendandi M, Albo C, Caballero MD. The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol 2007;18:652-7.
21. Corradini P, Tarella C, Zallio F, Dodero A, Zanni M, Valagussa P, Gianni AM, Rambaldi A, Barbui T, Cortelazzo S. Long-term follow-up of patients with peripheral T-cell lymphomas treated upfront with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 2006;20:1533-8.
22. Mercadal S, Briones J, Xicoy B, Pedro C, Escoda L, Estany C, Camós M, Colomo L, Espinosa I, Martínez S, Ribera JM, Martino R, Gutiérrez-García G, Montserrat E, López-Guillermo A, Grup per l'Estudi dels Limfomes de Catalunya I Balears (GELCAB). Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with in peripheral T-cell lymphoma. Ann Oncol 2008;19:958-63.
23. Reimer P, Rüdiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N, Engert A, Einsele H, Müller-Hermelink HK, Wilhelm M. Autologous stem cell transplantation (autoSCT) as first-line therapy in peripheral T cell lymphomas (PTCL). Results of a prospective multicenter study. J Clin Oncol 2009;27:106-13.
24. Tarella C, Caracciolo D, Ladetto M, Zallio F, Cuttica A, Ricca I, Gavarotti P, Bergui L, Corradini P, Pileri A. 11-yr follow-up of 184 non- Hodgkin's lymphoma (NHL) patients treated with high-dose sequential (HDS) chemotherapy and autograft: highest response and best outcome in germinal-center derived subtypes [abstract]. Blood 2000;96,769a
25. Mounier N, Gisselbrecht C, Brière J, Haioun C, Feugier P, Offner F, Recher C, Stamatoullas A, Morschhauser F, Macro M, Thieblemont C, Sonet A, Fabiani B, Reyes F. Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: a cohortstudy by the Groupe d'Etude del Lymphomes de l'Adulte. J Clin Oncol 2004;22,2826-2834.
26. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, ose JM, Connors JM, Federico M, Diehl V. Revised response riteria for malignant lymphoma. J Clin Oncol 2007;25:579-86.
27. Haioun C, Itti E, Rahmouni A, Brice P, Rain JD, Belhadj K, aulard P, Garderet L, Lepage E, Reyes F, Meignan M. [18F] luoro-2-deoxy-D-glucose positron emission tomography (FDGPET) n aggressive lymphoma: an early prognostic tool for predicting atient outcome. Blood 2005;106(4):1376-81.
28. Gallamini A, Rigacci L, Merli F, Nassi L, Bosi A, Capodanno I, uminari S, Vitolo U, Sancetta R, Iannitto E, Trentin L,Stelitano, Tavera S, Biggi A, Castagnoli A, Versari A, Gregianin M, Pelosi, Torchio P, Levis A. The predictive value of positron emission omography scanning performed after two courses of standard herapy on treatment outcome in advanced stage Hodgkin's disease. aematologica 2006;91:475-81.
29. Terasawa T, Lau J, Bardet S, Couturier O, Hotta T, Hutchings, Nihashi T, Nagai H. Fluorine-18-fluorodeoxyglucose positron mission tomography for interim response assessment of advancedstage odgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol 2009;27:1906-14.
30. Papajík T, Mysliveček M, Sedová Z, Buriánková E, Procházka V, Koranda P, Raida L, Kubová Z, Palová M, Kučerová L, Flodr P, Jarkovský J, Dušek L, Indrák K. Standardized uptake value of (18) F-FDG on staging PET/CT in newly diagnosed patients with different subtypes of non-Hodgkin's lymphoma. Eur J Haematol. 2010 Sep 28. doi: 10.1111/j.1600-0609.2010.01532.x. [Epub ahead of print].
31. Federico M, Clò V, Brugiatelli M, Carotenuto M, Gobbi PG, Vallisa D, Lombardo M, Avanzini P, Di Renzo N, Dini D, Baldini L, Silingardi V. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL. Haematologica 1998;83:800-11.
32. Colombat P, Biron P, Laporte JP, Cahn JY, Herve P, Gorin NC, Lamagnere JP, Philip T. BEAM protocol and autologous bone marrow transplantation in first chemosensitive relapse of non- Hodgkin's lymphomas. Eur J Cancer 1990;26:858.
33. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F,Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP. Report of an International Workshop to standardize Response Criteria for Non-Hodgkin's Lymphomas. J Clin Oncol 1999;17:1244-1253.
34. Nie HH, Hadlai H, Jenkins JG, Steinbrenner K, Bent DH. (1979)SPSS (Statistical Package for the Social Sciences). New York, NY: McGraw-Hill.
35. Kaplan EL, Meier P. Non parametric estimation from incomplete observation. JAMA 1958;53:457-481.
36. Escalón MP, Liu NS, Yang Y, Hess M, Walker PL, Smith TL, Dang NH. Prognostic factors and treatment of patients with T-cell non- Hodgkin lymphoma. Cancer 2005;103:2091-8.
37. Kyriakou C, Canals C, Goldstone A, Caballero D, Metzner B, Kobbe G, Kolb HJ, Kienast J, Reimer P, Finke J, Oberg G, Hunter A, Theorin N, Sureda A, Schmitz N. High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is a major determinant of outcome - Lymphoma Working Party of European Group for Blood and Marrow Transplantation. J Clin Oncol 2008;26:218-224.
38. Rodríguez J, Conde E, Gutiérrez A, Arranz R, León A, Marín J, Bendandi M, Albo C, Caballero MD. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur J Haematol 2007;79:32-8.
39. Rodríguez J, Conde E, Gutiérrez A, Arranz R, Gandarillas M, Leon A, Ojanguren J, Sureda A, Carrera D, Bendandi M, Moraleda J, Ribera JM, Albo C, Morales A, García JC, Fernández P, Cañigral G, Bergua J, Caballero MD. Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience. Eur J Haematol 2007;78:290-296.
40. Corradini P, Dodero A, Zallio F, Caracciolo D, Casini M, Bregni M, Narni F, Patriarca F, Boccadoro M, Benedetti F, Rambaldi A, Gianni AM, Tarella C. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 2004;22:2172-2176.
41. Ravandi F, Keating M. Alemtuzumab in T-cell malignances. In: Hillmen P, Witzig TE. Immunotherapy of lymphoid malignancies. Oxford: Atlas Medical Publishing, 2005. p.189-196.
42. Went P, Agostinelli C, Gallamini A, Piccaluga PP, Ascani S, Sabattini E, Bacci F, Falini B, Motta T, Paulli M, Artusi T, Piccioli M, Zinzani PL, Pileri SA. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic score. J Clin Oncol 2006;24:2472-2479.